In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2) and no patients ...
Cynata Therapeutics Limited ( OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST ...
Q3 2025 Earnings Call Transcript November 4, 2025 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...
The Takeout on MSN
13 Emergency Foods To Keep In Your Car When Winter Weather Hits
When temperatures plummet and snow piles up, it's always a good idea to stock the emergency kit in your car with food that's ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Health on MSN
10 Foods That Have Less Protein Than You Might Think
Some foods and drinks promoted as high in protein, such as peanut butter and yogurt, aren't actually as protein-rich as you'd ...
Gilead Sciences, Inc. today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in ...
A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...
Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961 No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961 ...
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback